Navigation Links
Rheumatoid Arthritis Therapeutics in Philippines
Date:4/6/2009

MANILA, Philippines, April 6 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life. In the Philippines, Serologic tests, Synovial fluid tests and X-rays are conducted to confirm the diagnosis of RA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Rheumatoid arthritis (RA) is one of the leading causes of significant debility among Filipinos, apart from asthma and cancer and about four times as many women as men have this disease. The prevalence is currently estimated to be approximately 0.06 percent National Nutrition & Health Survey (NNHeS) and is expected to increase to 0.07 percent by 2012. The treatment options are limited to conventional drugs such as disease-modifying antirheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs) as newer medications such as biologics are well beyond the affordability of the patients.

Frost & Sullivan, Research Analyst Sushma Rajan says, "The diagnosis of RA is based on clinical examination of symptoms, patient history, as well as some blood tests. RA cannot be confirmed or excluded by any one test. The most common test is rheumatoid factor (RF). The other supporting tests are: anti-cyclic citrullinated peptide (Anti-CCP), erythrocyte sedimentation rate (ESR), and X-ray."

"Recent work productivity studies have confirmed that better disease awareness and availability of treatment options have resulted in fewer patients ceasing to work and more patients reporting lower impact of their disease on work as well as family and social activities," she further elaborates.

The future of RA drugs in the Philippines is dependent on the availability of affordable and effective drugs to the patients. There is a steady demand for DMARDs and NSAIDs and their prescriptions are foreseen to increase, due to increased awareness and patient education, local production and distribution by companies.

Methotrexate (MTX), a DMARD (disease-modifying anti-rheumatic drugs) has been traditionally used to treat RA. It is also the most used form of treatment in rheumatoid arthritis, especially with generic forms available. Currently, combination therapies between DMARDs and NSAIDs (non-steroidal anti-inflammatory drugs) are commonly practiced.

DMARDs capture the majority of the RA therapeutics market owing to the availability of reimbursement for treatment with these drugs and their easy availability over the counter. DMARDs are expected to retain majority share in the forecast period as well.

According to Rajan, "Biologics are used in combination with DMARDs for moderate to severe RA patients. Some biologic drugs are currently reimbursed, if treated in government hospitals. Physicians opine that with more drugs brought into the hospital formularies, the usage of biologics would increase for treatment earlier in the disease."

Even though biologics are highly effective and recommended for treatment, they are likely to be the third line of treatment, due to their high cost. Physicians are willing to use biologics if they are listed in the hospital formulary and if they are affordable to their patients (current price range is seen to be out of reach of most patients). Physicians are of the opinion that more studies are required to make them feel confident in using biologics, but the cost of treatment is likely to restrain the high use of the drug class.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Emmie Kaur
    Corporate Communications - Healthcare, Asia Pacific
    DID: +603 6204 5913
    Email: emmie.kaur@frost.com

    Jasminder Kaur
    Corporate Communications - Healthcare, Asia Pacific
    DID: +65 6890 0937
    Email: jkaur@frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rheumatoid Arthritis Therapeutics in Thailand
2. Living Near Major Road May Boost Rheumatoid Arthritis Risk
3. Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia
4. BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
5. Immune cells from patients with rheumatoid arthritis have prematurely aged chromosomes
6. Rheumatoid Arthritis Drugs Raise Shingles Risk
7. Gene Therapy May Ease Rheumatoid Arthritis
8. Process found to play role in rheumatoid arthritis could lead to new treatment
9. Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis
10. Rheumatoid Arthritis Hits Women Harder
11. Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance ... beginning of a new charity campaign. As part of their ongoing community involvement ... In the belief that children deserve a voice, and in the spirit of ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley ... into Canada to provide its range of unique and advantaged protective solutions ... City that will provide bilingual customer service and marketing support. A new distribution ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... announced today that nominations will be accepted February 8, 2016 through May ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with substantially ... to make a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare ... helpful interventions and causes of chronic illness in children. , Very recent articles have ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 2016  The Parenteral Drug Association, Inc. (PDA), ... manufacturing sterile drug products, today announced the publication ... – With link to Comparison Spreadsheet. The ... U.S. FDA, the EU, the Pharmaceutical Inspection Convention/Scheme ... --> --> PDA,s Global Sterile ...
(Date:2/8/2016)... Feb.8, 2016 Cardiovascular Surgery Devices - ... GlobalData,s Medical Devices sector report, "Cardiovascular Surgery Devices ... overview of Cardiovascular Surgery Devices currently in pipeline ... The report provides comprehensive information on the ... at various stages of development. The report reviews ...
(Date:2/8/2016)... FAIRFIELD, N.J. , Feb. 8, 2016  Otsuka ... today announced that they have entered into a licensing ... OPA-15406 in the U.S. and Puerto Rico ... is a topical, non-steroidal phosphodiesterase IV (PDE-4) inhibitor, a ... --> --> In a Phase II ...
Breaking Medicine Technology: